

Caplyta

Naar cradinovic@burnsmc.com op 2024-12-09 14:35

[Details](#) [Headers](#) [Platte tekst](#)

- [caplyta_pi.pdf\(~709 KB\)](#)

Good afternoon,

We are a patient Association Tapering Medication in the Netherlands.

We read a LinkedIn-post about Caplyta (Lumateperone)

We wonder:

- whether the possibility of hyperbolic reduction has been taken into account when determining the dosages.

We assume that withdrawal symptoms were examined when reducing doses and after stopping?

How long was the use of this drug by the patients in the study?

How was a distinction made between withdrawal symptoms and relapse?

How long were patients followed after stopping?

<https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-submits-supplemental-new-drug>

--

Met vriendelijke groet, kind regards, thank you in advance,

Pauline Dinkelberg, chairperson

